Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Study shows drugs such as Vioxx and Celebrex were widely over-used long before recent problems

24.01.2005


Even before making the connection between drugs such as Vioxx and heart attacks, many doctors were becoming concerned that the heavily advertised drugs known as COX-2 inhibitors were being over-used, often by patients unlikely to benefit from this costly but innovative pharmaceutical class.



In the January 25, 2005, issue of the Archives of Internal Medicine, researchers from the University of Chicago and Stanford University School of Medicine use data from the National Center for Health Statistics to show that most of the growth in COX-2 use between 1999 and 2002 occurred in patients at little risk for side effects from the drugs COX-2s were developed to replace.

"We found a rapid nationwide shift away from older, inexpensive drugs with better established safety and efficacy to newer, costly drugs with no real history," said study author G. Caleb Alexander, M.D., M.S., instructor of medicine and a member of the MacLean Center for Clinical Medical Ethics at the University of Chicago.


"We pursued our analysis because of concerns that this was an example of overuse of a newer, more expensive class of medications," said co-author Randall S. Stafford, M.D., Ph.D., associate professor and Director of the Program on Prevention Outcomes and Practice at Stanford University. "As with other examples in the treatment of high blood pressure, diabetes and some infections, there appears to be a tendency for new drugs to be used in a wider array of situations than supported by scientific studies."

The COX-2 inhibitors, introduced early in 1999, were widely promoted as "super aspirin." Ordinary aspirin blocks both COX-2, which triggers inflammation, as well as COX-1, which protects the stomach lining and helps to decrease the risk of GI bleeds and stomach ulcers. These newer and far more expensive drugs were designed to target only COX-2 and to be used to treat patients with chronic inflammatory disorders such as arthritis.

The COX-2 inhibitors are no more effective in relieving pain than aspirin, ibuprofen, or any of the traditional non-steroidal anti-inflammatory drugs (NSAIDs), but they cause fewer of the gastrointestinal side effects that often trouble long-term high-dose NSAID users. In exchange for reduced GI risk, however, they cost 10 to 15 times as much as the drugs they replaced.

Within a year of being introduced, these drugs were bringing in billions of dollars of annual revenue. These drugs were also heavily promoted to physicians and to the general public. In 2000 alone, Vioxx was the most aggressively promoted drug on the market, including $161 million of direct-to-consumer advertising.

The researchers wondered how many of these prescriptions were going to patients who were not likely to benefit from them -- those with minimal risk of the gastrointestinal problems that can be caused by standard anti-inflammatory drugs.

They used data from two large nationally representative surveys of patient visits to doctors’ offices. Then they looked at the use of NSAIDs versus COX-2 prescriptions and compared them to treatment guidelines that stratify patients into different treatment groups based on the risks of gastrointestinal symptoms.

The guidelines recommend that patients with "very low risk" of GI problems (31% of patients in this study) or "low risk" (42%) receive traditional NSAIDs. Patients with "moderate risk" (25%) could receive COX-2s or NSAIDs depending on the expected length of treatment. Patients at "high risk" (2%) should take COX-2 inhibitors.

They authors found that the COX-2 inhibitors were frequently prescribed for all four groups and that they quickly gained market share, bounding from nowhere to 35 percent of anti-inflammatory prescriptions examined in 1999, the year they were introduced, to 61 percent by 2001.

They also found that most people who received prescriptions were at very low or low risk for GI bleeds and thus did not really need a COX-2 inhibitor. Despite the guidelines, 1.7 million, or 12 percent of patients at very low risk, received COX-2 prescriptions in 1999. That number increased to 7.6 million or 40 percent of very low risk patients by 2001 before declining slightly in 2002. At the same time, 6.8 million patients, or 40 percent of those at low risk, got COX-2 drugs in 1999, which increased to 17.6 million or 66 percent of low risk patients in 2002.

Over time, growth in COX-2 inhibitor use was most likely to come from those users least likely to benefit from these drugs.

By 2000, more patients were receiving COX-2 inhibitors than standard NSAIDs, including an estimated 16 million people suffering from congestive heart failure, or liver or kidney dysfunction, which are considered relative contra-indications to both COX-2s or NSAIDs.

"What we saw was widespread, rapid adoption of an interesting and promising but expensive and largely untested medication by millions of people with little or nothing to gain from long-term use," Alexander said. "The findings," the authors note, "demonstrate the challenge of limiting innovative therapies to the settings in which they are initially targeted and maximally cost-effective."

Carolanne Dai of the University of Chicago was the lead author of the paper. The research was supported by the MacLean Center for Clinical Medical Ethics at the University of Chicago, the National Institute of Aging, and the Agency for Healthcare Research and Quality.

John Easton | EurekAlert!
Further information:
http://www.uchospitals.edu

More articles from Health and Medicine:

nachricht Observing the cell's protein factories during self-assembly
15.06.2018 | Charité - Universitätsmedizin Berlin

nachricht Scientists unravel molecular mechanisms of Parkinson's disease
13.06.2018 | The Francis Crick Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: AchemAsia 2019 will take place in Shanghai

Moving into its fourth decade, AchemAsia is setting out for new horizons: The International Expo and Innovation Forum for Sustainable Chemical Production will take place from 21-23 May 2019 in Shanghai, China. With an updated event profile, the eleventh edition focusses on topics that are especially relevant for the Chinese process industry, putting a strong emphasis on sustainability and innovation.

Founded in 1989 as a spin-off of ACHEMA to cater to the needs of China’s then developing industry, AchemAsia has since grown into a platform where the latest...

Im Focus: First real-time test of Li-Fi utilization for the industrial Internet of Things

The BMBF-funded OWICELLS project was successfully completed with a final presentation at the BMW plant in Munich. The presentation demonstrated a Li-Fi communication with a mobile robot, while the robot carried out usual production processes (welding, moving and testing parts) in a 5x5m² production cell. The robust, optical wireless transmission is based on spatial diversity; in other words, data is sent and received simultaneously by several LEDs and several photodiodes. The system can transmit data at more than 100 Mbit/s and five milliseconds latency.

Modern production technologies in the automobile industry must become more flexible in order to fulfil individual customer requirements.

Im Focus: Sharp images with flexible fibers

An international team of scientists has discovered a new way to transfer image information through multimodal fibers with almost no distortion - even if the fiber is bent. The results of the study, to which scientist from the Leibniz-Institute of Photonic Technology Jena (Leibniz IPHT) contributed, were published on 6thJune in the highly-cited journal Physical Review Letters.

Endoscopes allow doctors to see into a patient’s body like through a keyhole. Typically, the images are transmitted via a bundle of several hundreds of optical...

Im Focus: Photoexcited graphene puzzle solved

A boost for graphene-based light detectors

Light detection and control lies at the heart of many modern device applications, such as smartphone cameras. Using graphene as a light-sensitive material for...

Im Focus: Water is not the same as water

Water molecules exist in two different forms with almost identical physical properties. For the first time, researchers have succeeded in separating the two forms to show that they can exhibit different chemical reactivities. These results were reported by researchers from the University of Basel and their colleagues in Hamburg in the scientific journal Nature Communications.

From a chemical perspective, water is a molecule in which a single oxygen atom is linked to two hydrogen atoms. It is less well known that water exists in two...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

Munich conference on asteroid detection, tracking and defense

13.06.2018 | Event News

2nd International Baltic Earth Conference in Denmark: “The Baltic Sea region in Transition”

08.06.2018 | Event News

ISEKI_Food 2018: Conference with Holistic View of Food Production

05.06.2018 | Event News

 
Latest News

Novel method for investigating pore geometry in rocks

18.06.2018 | Earth Sciences

Diamond watch components

18.06.2018 | Process Engineering

New type of photosynthesis discovered

18.06.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>